Marcondes França Junior

Assistant professor

University of Campinas
Country flagBrazil
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Introduction/Aims Natural history data for adult patients with spinal muscular atrophy (SMA) remain scarce, which is particularly relevant in the current therapeutic era. This study aimed to identify the most sensitive clinical, patient‐reported, and neurophysiological measures to detect short‐term disease progression in untreated adult SMA patients. Methods This prospective, one‐year longitudinal study included 21 genetically confirmed adult patients with SMA types 2B and 3. Clinician‐reported outcomes (CROs) included the Motor Function Measure (MFM), Hammersmith Functional Motor Scale Expanded (HFMSE), and Revised Upper Limb Module (RULM). Additionally, patient‐reported outcomes (PROs) were assessed using the Modified Fatigue Impact Scale (MFIS). Neurophysiological evaluations included compound muscle action potential (CMAP) amplitude and motor unit number index (MUNIX) recorded from the ulnar nerve. Sensitivity to change was determined using standardized response means (SRMs), and associations between clinical and neurophysiological data were analyzed via Spearman correlation. Results The majority of participants were non‐ambulatory (16/21). The MFM total score was the only outcome to show a statistically significant decline over 12 months ( p = 0.02), with the highest SRM (−0.55), indicating superior sensitivity. MFM also demonstrated the strongest correlations with CMAP amplitude ( ρ = 0.90) and MUNIX ( ρ = 0.75), compared to other CROs. No significant longitudinal changes were observed in RULM, HFMSE, MFIS, CMAP, or MUNIX. Discussion Among evaluated outcome measures, the MFM was the most sensitive to short‐term progression and most closely aligned with neurophysiological markers. These findings support the use of MFM as a primary outcome in clinical trials involving adult SMA patients.

Year:

2026

Background Hereditary Transthyretin Amyloidosis with polyneuropathy (ATTRv‐PN) is an autosomal dominant disorder characterized by TTR gene mutations, causing amyloid fibril deposition in peripheral nerves. Significant CNS involvement has been noted, emphasizing the necessity for advanced neuroimaging tools for early detection of CNS damage in ATTRv. Methods Comprehensive clinical assessments and multimodal MRI techniques, including FreeSurfer, TBSS and microbleed analysis, were utilized. The cohorts comprised 30 symptomatic patients (ATTRv‐PN), 19 presymptomatic patients (pre‐ATTRv‐PN), classified based on neuropathic signs, and 44 age‐ and sex‐matched controls. For cognitive assessment, we utilized the Addenbrooke's Cognitive Examination‐Revised. Results The ATTRv‐PN group had an average age of 51 years, while the pre‐ATTRv‐PN group averaged 41 years, with a sex ratio of 35% men to 65% women. Symptomatic patients experienced an average disease duration of 5 years, predominantly featuring the p.Val50Met genotype (73%). Brain imaging showed diffuse subcortical white matter alterations in ATTRv‐PN, while cortical thinning and microbleeds were infrequent. Cognitive assessments revealed significant differences, with symptomatic scoring lower in memory and verbal fluency than presymptomatic. Conclusion ATTRv‐PN involves cerebral white matter microstructural damage from early stages. Multimodal MRI serves as an accurate, non‐invasive tool for detecting CNS damage, improving our understanding of the disease spectrum.

Year:

2026

Fatigue is a frequent and under-recognized symptom in adults with spinal muscular atrophy (SMA). Although motor scales can detect disease progression, they may be insufficiently sensitive over short observation periods, particularly in patients with slower progression. To assess the prevalence and longitudinal course of fatigue in adult SMA patients using validated instruments. General perceived fatigue was assessed using the Fatigue Severity Scale (FSS), while the Modified Fatigue Impact Scale (MFIS) was used to evaluate multidimensional fatigue—comprising the physical, cognitive, and psychosocial domains. Additionally, we explored associations with motor function, neurophysiological parameters, and treatment status. Twenty-five adults with genetically confirmed SMA were evaluated at baseline and after one year using the FSS and MFIS. Motor function was measured by the Hammersmith Functional Motor Scale – Expanded, Revised Upper Limb Module (RULM), and Motor Function Measurement (MFM); neurophysiological assessment included Compound Muscle Action Potential (CMAP), Motor Unit Number Index (MUNIX) and repetitive nerve stimulation. Patients were stratified by fatigue status and use of disease-modifying therapies. Significant fatigue (FSS > 4) was observed in 60% of patients at baseline and 56% at follow-up. After 1 year, the prevalence of fatigue was significantly lower in treated patients (33.3%) compared to untreated ones (75%; p = 0.04). The MFIS scores remained stable across the physical, cognitive, and psychosocial domains. No associations were found between fatigue severity and age, disease duration, motor scale scores, or neurophysiological parameters. Fatigue is highly prevalent in adults with SMA and does not correlate with disease severity or motor/neurophysiological measures. Patients receiving disease-modifying therapies showed lower fatigue frequency, reinforcing the relevance of fatigue as a meaningful patient-reported outcome in this population.

Year:

2025

The cerebellum is a complex structure tightly connected to the cerebral cortex, brainstem, and spinal cord. It plays an important role in movement coordination and motor planning. Lately, it has been also recognized as a key component in cognitive circuits. The specific motor functions of the cerebellum include the control of the initiation, execution, and velocity of movements, as well as the maintenance of balance, motor coordination, and muscle tonus. Cerebellar lesions typically result in ataxia but can also lead to other manifestations, such as abnormal eye movements, severe vertigo, or impaired motor learning. Additionally, the cerebellum plays a key role in cognitive processes, with dysfunction leading to conditions such as the cerebellar cognitive affective syndrome (CCAS). Functional distinctions are evident between the cerebellar vermis, hemispheres, and flocculonodular lobe, each contributing to different motor and cognitive domains. In the current review, we address the current understanding of cerebellar anatomy and physiology, highlighting the most relevant correlations between lesion location and clinical symptomatology for practicing neurologists.

Year:

2025

Objective Spinocerebellar ataxia type 3 (SCA3) is a rare, inherited neurodegenerative disease. Here, we profile the spatial spread of atrophy across the whole brain, determine whether brain degeneration preferentially maps onto specific functional networks, and investigate the relationship between cerebellar and cerebral anatomical changes. Methods Whole-brain grey and white matter (GM and WM) voxel-based morphometry was performed on 408 individuals with SCA3 (82 pre-ataxic) and 293 controls. The SCA3 cohort was stratified by ataxia severity to investigate disease progression, with cerebellar GM atrophy mapped onto a task-based functional atlas. Volume was correlated with disease duration and intensity. Cerebrocerebellar volumetric covariance was assessed to determine whether atrophy was coupled between infra- and supratentorial regions. Results The pattern of atrophy is spatially consistent but progressive in magnitude across the disease course. The greatest atrophy was found in the pons, cerebellar WM, and cerebellar peduncles; correlations with disease severity and duration were also strongest in these regions. Cerebellar GM atrophy was greatest in functional regions associated with motor execution and planning, attention, and emotional processing. Sparse cerebral cortical atrophy appears only in the most severe disease subgroup, while striatal atrophy begins in the earliest stages. Reduced cerebrocerebellar structural covariance is observed in SCA3 participants versus controls. Interpretation While cerebellar and brainstem atrophy become more severe, the pattern of atrophy remains largely consistent as SCA3 progresses. Cerebellar GM degeneration occurs in regions associated with motor, cognitive, and affective control, in line with clinical presentation. Cerebellar atrophy is not directly mirrored by cerebral changes.

Year:

2025

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired autoimmune disorder that leads to progressive motor and sensory impairment, resulting in significant morbidity. While the incidence rates vary, CIDP remains a challenging condition requiring a standardized and optimized approach to diagnosis and management. In Brazil, a middle-income country with substantial regional disparities in healthcare access, the availability of specialized neuromuscular centers is uneven, creating obstacles to timely and effective treatment. To address these challenges, the Brazilian Academy of Neurology (Academia Brasileira de Neurologia, ABN, in Portuguese) has developed national recommendations for the diagnosis, management, and treatment of CIDP, tailored to the country's healthcare resources. This consensus outlines standardized diagnostic criteria that incorporate electrophysiological and imaging findings, and it emphasizes key differential diagnoses to enhance diagnostic accuracy. The recommendations were developed through expert panel discussions and a non-systematic review of the literature. The recommended treatment strategies include first-line therapies such as corticosteroids, intravenous immunoglobulin (IVIg), and plasmapheresis, with guidance on escalation and titration of immunosuppressive therapy in refractory cases. By emphasizing early intervention to prevent axonal degeneration and disability, these guidelines aim to improve clinical outcomes and support public health policies within the Brazilian National Health System (Sistema Único de Saúde, SUS, in Portuguese), ensuring equitable and effective CIDP management across the country.

Year:

2025

Over the last decade, whole-exome sequencing (WES) has become a standard diagnostic tool, significantly transforming the landscape of clinical genetics and playing a pivotal role in the diagnosis of neurogenetic diseases. This revolutionary shift has left a lasting impact on the field of neurology in Brazil. The current review article examines key developments and milestones achieved in Brazil through the application of WES in neurology and discusses forthcoming challenges and essential steps to advance molecular diagnosis. Several studies report the use of WES to diagnose genetic disorders with neurological manifestations in Brazil, underscoring the growing importance of molecular diagnosis in neurogenetics. These studies often provide detailed phenotypic analyses and clinical descriptions, offering valuable insights into the genetic underpinnings of several neurological conditions. Many reports highlight the use of WES in the investigation of complex neurological conditions in Brazil, such as neurodevelopmental disorders, hereditary spastic paraplegia, movement disorders, and ataxia. The discovery of new genes implicated in monogenic diseases with neurological manifestations through WES was a significant breakthrough. Despite these advances, the availability of large cohort studies on rare diseases in Brazil remains limited, hindering the ability to generalize findings and explore the full spectrum of genetic diversity. However, a few larger cohort studies have substantially contributed to our understanding of rare diseases and specific neurological disorders. While WES has limitations and may eventually be supplanted by more advanced diagnostic tools, it left a permanent mark on the neurology field in Brazil. The field of neurogenetics is set to become increasingly important in the future.

Year:

2025

Niemann-Pick type-C (NPC) disease is a rare genetic condition with a clinical spectrum ranging from a fatal prenatally-presenting and quickly lethal disorder to an adult-onset chronic neurodegenerative condition. Given the scarcity of information regarding NPC disease in Brazil, a group of experts decided to discuss some disease-related aspects at the national level. The present manuscript describes the results of a Brazilian consensus meeting conducted to propose recommendations for the diagnosis, management, and follow-up of NPC disease in Brazil, considering the clinical practice point of view. These recommendations include patient characteristics on clinical presentation, as systemic and neurological manifestations according to the age group and atypical manifestations; a flowchart for diagnostic confirmation, considering the Brazilian scenario; and treatment, encompassing disease-modifying therapy, supportive care, and patients' follow-up. The expert panel provided an objective basis of recommendations on NPC diagnosis and management in Brazil. The authors expect that this manuscript will help clinicians to identify, adequately treat and follow-up NPC patients in Brazil.

Year:

2025

Introduction/Aims Language is frequently affected in patients with sporadic amyotrophic lateral sclerosis (sALS), with reduced performance in naming, syntactic comprehension, grammatical expression, and orthographic processing. However, the language profile of patients with familial type 8 ALS (ALS8), linked to p.P56S VAPB mutation, remains unclear. We investigated language in patients with ALS8 by examining their auditory comprehension and verbal production. Methods We included three groups of participants: (1) patients with sALS ( n = 20), (2) patients with familial ALS8 ( n = 22), and (3) healthy controls ( n = 21). The groups were matched for age, sex, and education level. All participants underwent a comprehensive language battery, including the Boston Diagnostic Aphasia Examination, the reduced Token test, letter fluency, categorical fluency (animals), word definition from the Cambridge Semantic Memory Research Battery, and a narrative discourse analysis. Participants also were evaluated using Addenbrooke's Cognitive Exam‐Revised Version, the Hospital Anxiety and Depression Scale, and the ALS Functional Rating Scale‐Revised. Results Compared to controls, sALS and ALS8 patients had impaired performance on oral (syntactic and phonological processing) comprehension and inappropriate discourse cohesion. sALS and ALS8 did not differ in any language measure. There was no correlation between language scores and functional and psychiatric scales. Discussion ALS8 patients exhibit language deficits that are independent of motor features. These findings are consistent with the current evidence suggesting that ALS8 has prominent non‐motor features.

Year:

2024

Neuromuscular diseases (NMD) include a broad group of medical conditions with both acquired and genetic causes. In recent years, important advances have been made in the treatment of genetically caused NMD, and most of these advances are due to the implementation of therapies aimed at gene regulation. Among these therapies, gene replacement, small interfering RNA (siRNA), and antisense antinucleotides are the most promising approaches. More importantly, some of these therapies have already gained regulatory approval or are in the final stages of approval. The review focuses on motor neuron diseases, neuropathies, and Duchenne muscular dystrophy, summarizing the most recent developments in gene-based therapies for these conditions.

Year:

2024

Year:

2024

Year:

2023

Collaborators (17)

Benjamin Bender

University Hospital

GERMANY
View details

Giulia Coarelli

Institut du Cerveau et de la Moelle Épinière

FRANCE
View details

Ian H. Harding

Group Leader

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Thiago Rezende

Associate Researcher

University of Campinas

BRAZIL
View details

Chiadi Onyike

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Andreas Deistung

University Hospital Halle (Saale)

GERMANY
View details

Kathrin Reetz

Full Professor for Translational Neurodegeneration

-

GERMANY
View details

Fernando Cendes

Full Professor

University of Campinas

BRAZIL
View details

Matthis Synofzik

Professor

Hertie Institute for clinical brain research

GERMANY
View details

Alexandra Durr

Professor, MD, PhD

Sorbonne Université

FRANCE
View details

Bart van de Warrenburg

Associate professor, neurologist, principal investigator

Radboud Universitair Medisch Centrum

NETHERLANDS
View details

David Arpin

University of Florida

UNITED STATES
View details

Dagmar Timmann

University Hospital Essen

GERMANY
View details

Jennifer Faber

Head of Ataxia Clinic

University Hospital Bonn

GERMANY
View details

Jerry L. Prince

William B Kouwenhoven Professor

Johns Hopkins University

UNITED STATES
View details

Gulin Oz

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Henry Paulson

University of Michigan

UNITED STATES
View details